T1	CHEM 55 64	nivolumab
#1	AnnotatorNotes T1	C3657270; nivolumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T2	CHEM 84 94	ipilimumab
#2	AnnotatorNotes T2	C1367202; ipilimumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T3	CHEM 109 118	nivolumab
#3	AnnotatorNotes T3	C3657270; nivolumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T4	CHEM 126 136	ipilimumab
#4	AnnotatorNotes T4	C1367202; ipilimumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T5	PROC 148 159	tratamiento
#5	AnnotatorNotes T5	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T6	PROC 184 202	resección completa
#6	AnnotatorNotes T6	C0015250; Complete excision; Therapeutic or Preventive Procedure
T7	DISO 206 214	melanoma
#7	AnnotatorNotes T7	C0025202; melanoma; Neoplastic Process
T8	PROC 270 298	Estudio fase 3, aleatorizado
T9	PROC 302 329	inmunoterapia en adyuvancia
T10	CHEM 352 361	nivolumab
#8	AnnotatorNotes T10	C3657270; nivolumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T11	CHEM 364 374	ipilimumab
#9	AnnotatorNotes T11	C1367202; ipilimumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T12	CHEM 384 394	ipilimumab
#10	AnnotatorNotes T12	C1367202; ipilimumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T13	CHEM 397 406	nivolumab
#11	AnnotatorNotes T13	C3657270; nivolumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T14	PROC 410 421	monoterapia
#12	AnnotatorNotes T14	C4763675; Single Agent Therapy; Therapeutic or Preventive Procedure
T15	PROC 433 451	resección completa
#13	AnnotatorNotes T15	C0015250; Complete excision; Therapeutic or Preventive Procedure
T16	DISO 455 463	melanoma
#14	AnnotatorNotes T16	C0025202; melanoma; Neoplastic Process
T17	DISO 520 528	Melanoma
#15	AnnotatorNotes T17	C0025202; melanoma; Neoplastic Process
T18	DISO 578 586	melanoma
#16	AnnotatorNotes T18	C0025202; melanoma; Neoplastic Process
T19	Observation 620 645	sin pruebas de enfermedad
#17	AnnotatorNotes T19	C1518340; No Evidence of Disease; Finding
T20	PROC 663 681	resección completa
#18	AnnotatorNotes T20	C0015250; Complete excision; Therapeutic or Preventive Procedure
T21	DISO 758 766	Melanoma
#19	AnnotatorNotes T21	C0025202; melanoma; Neoplastic Process
T22	PROC 1075 1104	tratamiento previo oncológico
T23	DISO 1113 1121	melanoma
#20	AnnotatorNotes T23	C0025202; melanoma; Neoplastic Process
T24	PROC 1131 1138	cirugía
#21	AnnotatorNotes T24	C0543467; Operative Surgical Procedures; Therapeutic or Preventive Procedure
T25	DISO 1158 1166	melanoma
#22	AnnotatorNotes T25	C0025202; melanoma; Neoplastic Process
T26	PROC 1179 1206	radioterapia (RT) adyuvante
T27	PROC 1218 1227	resección
#23	AnnotatorNotes T27	C0728940; Excision; Therapeutic or Preventive Procedure
T28	DISO 1231 1268	lesiones del sistema nervioso central
#24	AnnotatorNotes T28	C0742468; Central nervous system lesion; Disease or Syndrome
T29	ANAT 1244 1268	sistema nervioso central
#25	AnnotatorNotes T29	C1269563; Entire central nervous system; Body System | C3714787; Central Nervous System; Body System
T30	ANAT 1270 1273	SNC
#26	AnnotatorNotes T30	C1269563; Entire central nervous system; Body System | C3714787; Central Nervous System; Body System
T31	DISO 1317 1333	melanoma de úvea
T32	DISO 1381 1407	enfermedad autoinmunitaria
#27	AnnotatorNotes T32	C0004364; Autoimmune Diseases; Disease or Syndrome
T33	PROC 1442 1453	Tratamiento
#28	AnnotatorNotes T33	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T34	CHEM 1548 1569	anticuerpos anti-PD-1
T35	CHEM 1465 1475	interferón
#29	AnnotatorNotes T35	C0021747; Interferons; Amino Acid, Peptide, or Protein · Immunologic Factor
T36	CHEM 1571 1581	anti-PD-L1
T37	CHEM 1583 1593	anti-PD-L2
T38	CHEM 1608 1619	anti-CTLA-4
T39	CHEM 1638 1648	anticuerpo
#30	AnnotatorNotes T39	C0003241; Antibodies; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T40	CHEM 1651 1762	fármaco que se dirija específicamente a la coestimulación de los linfocitos T o a las vías del punto de control
#31	AnnotatorNotes T40	C3192215; Selective T Cell Costimulation Blocker; Pharmacologic Substance (?) | C4684977; Immune Checkpoint Inhibitors; Pharmacologic Substance (?)
T41	ANAT 1716 1728	linfocitos T
#32	AnnotatorNotes T41	C0039194; T-Lymphocyte; Cell
T42	CHEM 1595 1605	anti-CD137
T43	DISO 691 697	lesión
#33	AnnotatorNotes T43	C0221198; Lesion; Finding
T44	PROC 800 842	resecado quirúrgicamente de forma completa
T45	DISO 1144 1150	lesión
#34	AnnotatorNotes T45	C0221198; Lesion; Finding
T46	ANAT 1329 1333	úvea
#35	AnnotatorNotes T46	C0042160; Uvea; Body Part, Organ, or Organ Component | C1281287; Entire uveal tract; Body Part, Organ, or Organ Component
T47	Date 12 16	2016
T48	LIVB 163 172	pacientes
#36	AnnotatorNotes T48	C0030705; Patients; Patient or Disabled Group
T51	LIVB 564 573	Pacientes
#37	AnnotatorNotes T51	C0030705; Patients; Patient or Disabled Group
T53	Neg_cue 620 623	sin
T56	Duration 853 867	las 12 semanas
T58	Neg_cue 1071 1074	Sin
T61	LIVB 1367 1376	Pacientes
#38	AnnotatorNotes T61	C0030705; Patients; Patient or Disabled Group
T62	Spec_cue 1430 1438	sospecha
T64	Duration 1497 1505	<6 meses
T50	PHYS 1694 1728	coestimulación de los linfocitos T
#40	AnnotatorNotes T50	C1622572; T cell costimulation; Cell Function
T52	PROC 1337 1341	Peso
#41	AnnotatorNotes T52	C2985231; Body Weight Measurement; Diagnostic Procedure
T54	DISO 721 728	recaída
#42	AnnotatorNotes T54	C0699753; Cancer Relapse; Neoplastic Process
T55	Spec_cue 711 720	riesgo de
A2	Assertion T22 Negated
A3	Assertion T32 Speculated
A5	Assertion T54 Speculated
A4	Status T33 History_of
A6	Status T35 History_of
A7	Status T34 History_of
A8	Status T36 History_of
A9	Status T37 History_of
A10	Status T42 History_of
A11	Status T38 History_of
A12	Status T39 History_of
A13	Status T40 History_of
A14	Status T31 History_of
A15	Status T44 History_of
A16	Status T20 History_of
A17	Status T6 History_of
A18	Status T15 History_of
A19	Status T22 History_of
A20	Status T24 History_of
A21	Status T26 History_of
A22	Status T27 History_of
A23	Status T32 History_of
#43	AnnotatorNotes T8	C0034656; Randomization; Research Activity + C0282461; Phase 3 Clinical Trials; Research Activity
#44	AnnotatorNotes T9	C0021083; Immunotherapy; Therapeutic or Preventive Procedure + C0677850; Adjuvant therapy; Therapeutic or Preventive Procedure
#45	AnnotatorNotes T26	C0242939; Radiotherapy, Adjuvant; Therapeutic or Preventive Procedure
#46	AnnotatorNotes T31	C0220633; Uveal melanoma; Neoplastic Process 
#47	AnnotatorNotes T34	C4289971; Anti-PD-L1 Monoclonal Antibody; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
#48	AnnotatorNotes T36	C4289971; Anti-PD-L1 Monoclonal Antibody; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
#49	AnnotatorNotes T42	C4732974; Anti-CD137 Monoclonal Antibody; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
#50	AnnotatorNotes T38	C4289973; Anti-CTLA-4 Monoclonal Antibody; Amino Acid, Peptide, or Protein
T57	CONC 624 645	pruebas de enfermedad
A24	Assertion T57 Negated
R1	Negation Arg1:T53 Arg2:T57	
R2	Speculation Arg1:T55 Arg2:T54	
R3	Negation Arg1:T58 Arg2:T22	
R4	Speculation Arg1:T62 Arg2:T32	
R5	Combined_with Arg1:T1 Arg2:T2	
T59	Quantifier_or_Qualifier 119 123	solo
R6	Has_Quantifier_or_Qualifier Arg1:T3 Arg2:T59	
T60	Quantifier_or_Qualifier 137 141	solo
R7	Has_Quantifier_or_Qualifier Arg1:T4 Arg2:T60	
R8	Used_for Arg1:T1 Arg2:T5	
R9	Used_for Arg1:T3 Arg2:T5	
R10	Used_for Arg1:T4 Arg2:T5	
R11	Experiences Arg1:T48 Arg2:T1	
R12	Experiences Arg1:T48 Arg2:T3	
R13	Experiences Arg1:T48 Arg2:T4	
R14	After Arg1:T1 Arg2:T6	
R15	After Arg1:T3 Arg2:T6	
R16	After Arg1:T4 Arg2:T6	
R17	Experiences Arg1:T48 Arg2:T6	
R18	Experiences Arg1:T48 Arg2:T7	
T63	Quantifier_or_Qualifier 218 247	estadio IIIb/c/d o estadio IV
R19	Has_Quantifier_or_Qualifier Arg1:T7 Arg2:T63	
T65	Quantifier_or_Qualifier 467 496	estadio IIIb/c/d o estadio IV
R20	Has_Quantifier_or_Qualifier Arg1:T16 Arg2:T65	
R21	Combined_with Arg1:T10 Arg2:T11	
R23	After Arg1:T12 Arg2:T15	
R24	After Arg1:T13 Arg2:T15	
R25	Used_for Arg1:T12 Arg2:T14	
R26	Used_for Arg1:T13 Arg2:T14	
T66	Quantifier_or_Qualifier 529 537	avanzado
#51	AnnotatorNotes T66	C0205179; Advanced phase; Qualitative Concept | C1522484; metastatic qualifier; Functional Concept
R27	Has_Quantifier_or_Qualifier Arg1:T17 Arg2:T66	
T67	Quantifier_or_Qualifier 590 619	estadio IIIb/c/d o estadio IV
R28	Has_Quantifier_or_Qualifier Arg1:T18 Arg2:T67	
R29	Experiences Arg1:T51 Arg2:T18	
R31	Overlap Arg1:T18 Arg2:T19	
R32	Experiences Arg1:T51 Arg2:T20	
R33	After Arg1:T18 Arg2:T20	
R34	After Arg1:T19 Arg2:T20	
R35	Experiences Arg1:T51 Arg2:T43	
R36	Before Arg1:T18 Arg2:T54	
T68	Observation 706 720	alto riesgo de
#52	AnnotatorNotes T68	C0332167; High risk of; Finding
R37	Before Arg1:T68 Arg2:T54	
R38	Experiences Arg1:T51 Arg2:T68	
R39	Overlap Arg1:T18 Arg2:T68	
R40	Overlap Arg1:T19 Arg2:T68	
R41	Before Arg1:T20 Arg2:T54	
T69	Quantifier_or_Qualifier 770 799	estadio IIIb/c/d o estadio IV
R42	Has_Quantifier_or_Qualifier Arg1:T21 Arg2:T69	
R43	Overlap Arg1:T44 Arg2:T56	
T70	Observation 881 908	participación en el estudio
#53	AnnotatorNotes T70	C1278516; Patient participation status; Finding (?)
R44	Before Arg1:T44 Arg2:T70	
T71	PROC 901 908	estudio
#54	AnnotatorNotes T71	C0008976; Clinical Trials; Research Activity
R45	Before Arg1:T44 Arg2:T71	
T72	Observation 970 986	capaz de caminar
#55	AnnotatorNotes T72	C2712089; Able to walk (finding); Finding 
T73	Observation 989 1046	llevar a cabo actividades como pequeñas tareas domésticas
#56	AnnotatorNotes T73	C4534513; Performing activities of daily living; Finding (?)
T74	Observation 917 941	tener actividad completa
T75	Observation 1049 1067	trabajo de oficina
#57	AnnotatorNotes T75	C2230102; working as office worker; Finding (?)
R46	After Arg1:T26 Arg2:T27	
R47	Location_of Arg1:T30 Arg2:T28	
R48	Location_of Arg1:T29 Arg2:T28	
R49	Location_of Arg1:T46 Arg2:T31	
T76	Result_or_Value 1342 1363	menor o igual a 40 kg
R50	Has_Result_or_Value Arg1:T52 Arg2:T76	
R51	Experiences Arg1:T61 Arg2:T32	
T77	Quantifier_or_Qualifier 1408 1414	activa
#58	AnnotatorNotes T77	C0205177; Active; Qualitative Concept | C0679217; Active State; Idea or Concept
R52	Has_Quantifier_or_Qualifier Arg1:T32 Arg2:T77	
R53	Used_for Arg1:T35 Arg2:T33	
R54	Before Arg1:T35 Arg2:T64	
T78	Observation 1518 1545	participación en el estudio
#59	AnnotatorNotes T78	C1278516; Patient participation status; Finding (?)
R55	Before Arg1:T35 Arg2:T78	
T79	PROC 1538 1545	estudio
#60	AnnotatorNotes T79	C0008976; Clinical Trials; Research Activity
R56	Before Arg1:T35 Arg2:T79	
T80	Observation 1442 1453;1486 1496	Tratamiento completado
#61	AnnotatorNotes T80	C0580352; Treatment completed; Finding
R57	Overlap Arg1:T80 Arg2:T64	
R58	Used_for Arg1:T34 Arg2:T33	
R59	Used_for Arg1:T36 Arg2:T33	
R60	Used_for Arg1:T37 Arg2:T33	
R61	Used_for Arg1:T42 Arg2:T33	
R62	Used_for Arg1:T38 Arg2:T33	
R63	Used_for Arg1:T39 Arg2:T33	
R64	Used_for Arg1:T40 Arg2:T33	
R66	Used_for Arg1:T10 Arg2:T9	
R67	After Arg1:T9 Arg2:T15	
R22	After Arg1:T10 Arg2:T15	
R68	Used_for Arg1:T12 Arg2:T9	
R69	Used_for Arg1:T13 Arg2:T9	
R70	Experiences Arg1:T51 Arg2:T54	
#39	AnnotatorNotes T59	C0205171; Singular; Quantitative Concept
#62	AnnotatorNotes T60	C0205171; Singular; Quantitative Concept
#63	AnnotatorNotes T44	C5421113; Complete Resection; Therapeutic or Preventive Procedure
R30	Causes Arg1:T18 Arg2:T43	
R71	Causes Arg1:T25 Arg2:T45	
R72	Causes Arg1:T23 Arg2:T45	
A1	Experiencer T48 Patient
A25	Experiencer T51 Patient
A26	Experiencer T61 Patient
A27	Assertion T80 Hypothetical
A28	Assertion T64 Hypothetical
A29	Assertion T78 Hypothetical
